Conference abstract · 6 Oct 2014
Conference abstractPublished 28 Nov 2016
Development of novel inhibitors targeting NS3/4A protease of hepatitis C virus
Wroclaw University of Technology, Poland
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Currently about 130-150 million people live with chronic hepatitis C virus infection worldwide of which many patients remain asymptomatic with a high chance of developing liver cirrhosis. One of the developed anti-HCV therapies target a serine protease crucial for viral replication-the bifunctional non-structural protein 3 (NS3/4A) of two separate functional activities: Serine protease and NTPase/RNA helicase activity. Moreover, due to its ability to destroy several important cellular proteins NS3/4A is able to block innate immune pathways and modulate growth factor signaling pathways. All of already approved for the treatment of HCV infection compounds display a reversible-type of inhibition. Nevertheless, the appearance of the inhibitor-resistant mutant strains limits the efficiency of the overall treatment. Irreversible protease inhibitors, such as Ã?±-aminophosphonic inhibitors, therefore, might represent a new therapeutic option. These compounds strike a balance between reactivity and chemical stability. Their mechanism of action relies on the phosphonylation of a serine residue which leads to the formation of an irreversible covalent complex. Here we report the design and biological evaluation of highly potent, active site-directed and irreversible inhibitors of HCV NS3/4A protease. One of the advantages of Ã?±-aminophosphonic inhibitors is their specificity of action toward serine proteases and lack of reactivity with cysteine, aspartyl and metalloproteinases. Considering high stability in human plasma, irreversible mechanism of action and low toxicity Ã?±-aminoalkylphosphonates represent an interesting class of inhibitors for novel antiviral agentsâÂ?Â? development.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 7 Jun 2017
Identification of thiadiazinyl-coumarin derivatives as dengue virus-2 NS2B/NS3 protease inhibitors
Research article · 2014
Identification of Novel Hepatitis C Virus NS3-4A Protease Inhibitors by Virtual Screening Approach
Conference abstract · 29 Oct 2012
Screening for novel anti-dengue virus NS3/NS2B inhibitor
Conference abstract · 6 Oct 2014
Design and synthesis of the West Nile Virus NS2B/NS3 protease
More from this journal
The newest in Journal of Antivirals & Antiretrovirals.
Conference abstract · 23 Jun 2025
How is really working adaptive immune system in mammals? A novel conception and reverse pathway theory, which will bring novel multibillion super-antibody (sab) technology for curing of all of infectious diseases and cancer!
Conference abstract · 23 Jun 2025
Exploring signature proteins to design a novel multi-epitope vaccine candidate against Mycobacterium tuberculosis: An in-silico approach
Conference abstract · 23 Jun 2025
Correlation Between the Rh/ABO system and infection due to sars cov2 in morocco
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Antivirals & Antiretrovirals
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Marcin Sienczyk”
- BylineArticles whose byline prints “Marcin Skorenski”
- BylineArticles whose byline prints “Jozef Oleksyszyn”

